Skip to content
Main Navigation
Aveo Oncology Logo
  • About
  • Partnerships
  • Our Science
  • Medical Information
  • Newsroom
  • Contact
    • About
      • Culture
      • Management Team
      • Careers
      • Compliance and Ethics
      Partnerships
      • Scientific Advisory Committee
      Our Science
      • FOTIVDA
      • Ficlatuzumab
      • AV-380
      • Patents
      Medical Information
      • Publications & Presentations
      • Medical Grants – IST
      • Medical Grants – CME
      • Expanded Access Policy
      Newsroom
      Contact
  • About
    • Culture
    • Management Team
    • Careers
    • Compliance and Ethics
  • Partnerships
    • Scientific Advisory Committee
  • Our Science
    • FOTIVDA
    • Ficlatuzumab
    • AV-380
    • Patents
  • Medical Information
    • Publications & Presentations
    • Medical Grants – IST
    • Medical Grants – CME
    • Expanded Access Policy
  • Newsroom
  • Contact

Publications and presentations

AVEO Oncology allows you to access a number of published papers and presentations outlining our clinical data that were given at premier conferences and symposia around the world.


June 10, 2022
PresentationTivozanib

ASCO 2022: Activity of Tivozanib in Non-Clear Cell Renal Cell Carcinoma (nccRCC): Subgroup Analysis From a Phase 2 Randomized Discontinuation Trial

June 10, 2022
PresentationTivozanib

ASCO 2022: Maturation of Overall Survival in TIVO-3 With Long-Term Follow-Up

February 14, 2022
PresentationTivozanib

ASCO GU 2022: TiNivo-2: A Phase 3, Randomized, Controlled, Open-Label Study to Compare Tivozanib in Combo With Nivolumab to Tivozanib Monotherapy in Patients With RCC Following 1 or 2 Lines of Therapy in Which at Least One Line Has an Immune CPI

February 14, 2022
PresentationTivozanib

ASCO GU 2022: Long-Term PFS From TIVO-3: Tivozanib (TIVO) vs Sorafenib (SOR) in Relapsed/Refractory (R/R) Advanced RCC

January 24, 2022
PresentationTivozanib

ASCO GI 2022: A Phase 1b/2 Open Label Study of Tivozanib in Combination with Durvalumab in Subjects with Advanced Hepatocellular Carcinoma: DEDUCTIVE

January 24, 2022
PresentationTivozanib

ASCO GI 2022: A Phase 1b/2 Study of Tivozanib in Combination with Durvalumab in Subjects with Advanced Hepatocellular Carcinoma (DEDUCTIVE): Efficacy Results in Previously Untreated Patients

« Previous 1 2 3 4 5 6 … 15 Next »

Looking for medical information? Contact our Medical Information Team at

AVEOmedicalinformation@aveooncology.com.

  • Careers
  • Terms of Use
  • Privacy Policy
  • LG Chem
  • Code of Business Conduct and Ethics